Navigation Links
Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
Date:8/3/2009

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eight percent in the drug market for benign prostatic hyperplasia and male lower urinary tract symptoms in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Generic erosion will offset market growth of more than seven percent that will be driven by the uptake of emerging agents from 2008 to 2013.

The new Pharmacor report entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms finds that the market is saturated with effective, well-established agents. The market is also concentrated as, in 2008, tamsulosin garnered just over half of all major-market sales for benign prostatic hyperplasia. Tamsulosin, the most widely-used alpha blocker for the indication, is marketed by Boehringer Ingelheim as Flomax/Josir/Alna/Pradif/Urolosin and by Astellas as Omix/Omnic/Flomaxtra/Harnal. Generic versions of tamsulosin have been available in Europe and Japan since 2006 and, in the first half of 2010, the drug will be generically available in the United States as well. As a result of generic competition, tamsulosin's annual major-market sales will plummet 41 percent between 2008 and 2013, according to the report.

The report also finds that, while symptom relief remains the primary concern in treating the disease, drug development for benign prostatic hyperplasia has focused on improving dosing convenience and slowing disease progression. Owing to its dosing convenience, GlaxoSmithKline's tamsulosin/dutasteride fixed-dose combination Duodart will likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceu
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Generic prostate drug helps find high-risk cancers early
7. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
9. FDA Announces Initiative to Bolster Generic Drug Program
10. FDA Struggles to Keep Pace With Requests for Generics
11. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Oxford, UK, September 17, 2014 The International Journal ... has opened up its archive of previously published content: after ... read. A key aim of the IJS is ... hoped that by making these articles available to all will ... Editor-in-Chief of IJS said, "The journal has always ...
(Date:9/17/2014)... WA (PRWEB) September 17, 2014 A ... in fiscal year 2010 revealed 3.2% of these patients developed ... and 2.4% labeled as superficial SSIs. The average difference for ... 876, after adjustments. , The study, conducted by Marin Schweizer, ... the University of Iowa, found the treatment costs for the ...
(Date:9/17/2014)... September 17, 2014 The probability of ... with regular screening and examination, a healthy diet could ... of Epicure with the Chef MDs, renowned ... Paul Rusilko to prepare a delicious Fish Moilee. , ... diets that influence risk of prostate cancer, uncommonly found ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... September 17, 2014 Kamut International is ... a key ingredient in Michael Angelo’s new “Made With ... new fully organic lasagna ready made, frozen meal. Michael ... pastas and these new products align well with Kamut ... all KAMUT® Brand wheat must be grown certified organic. ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2
... A large-scale data review by researchers in China of ... the endoscopic procedure to be safe and effective for ... a pooled detection rate of 68.1 percent for all ... be the most common indication, with a relatively high ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 2011) Researchers in Japan have completed a study showing ... pulp can be grafted and produce bone regeneration between parents ... of Cell Transplantation (20:7), now freely ... a number of reasons, and autogenous bone grafting - using ...
... , MONDAY, Sept. 26 (HealthDay News) -- ... inhibitor (SSRI) antidepressants and antiplatelet drugs such as aspirin ... those who take anti-clotting drugs only, a new study ... and Lexapro. Antiplatelet drugs prevent blood cells from ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
... Eating fruits and vegetables may reduce the risk of some ... examined the diets of 918 colorectal cancer patients and 1,021 ... consumption of certain vegetables and fruits were associated with a ... -- that is, the upper and lower portions of the ...
Cached Medicine News:Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Fortune Oil ... officially changed its name to Manzo Pharmaceuticals, Inc. with ... to take effect today, September 17, 2014. Also taking ... The approval is a pivotal event in ... . Mr. Manzo explained, "We could not proceed with ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... 2014 Mindray (NYSE: MR)announced its new generation ... system has been showcased for the first time at ... September, and is scheduled for availability in the U.S. ... the most efficient workhorse in the mid-range segment, the ... perfectly optimized user experience including a gesture-sensitive touch screen, ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
The Flash MiniLabeler products can be configured to label microplates, tubes, vials, glass slides, circuit boards and a wide array of small products. Systems perform wrap around (tube or package) lab...
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Modular Slide Storage Cabinet has a durable cold rolled steel construction with baked on epoxy finish. Drawers slide smoothly and quietly....
Store microscope slides with ease, speed, efficiency....
Medicine Products: